A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Latest Information Update: 03 Jun 2025
At a glance
- Drugs Cytarabine (Primary) ; Eganelisib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Stelexis Therapeutics
Most Recent Events
- 16 May 2025 Status changed from not yet recruiting to recruiting.
- 07 Aug 2024 New trial record